Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 2 (1)

Trial Status

Recruiting3
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06955286Recruiting

Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion

NCT06833437Not ApplicableRecruiting

68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)

NCT06106295Phase 2Active Not RecruitingPrimary

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

NCT05357456RecruitingPrimary

Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study

Showing all 4 trials

Research Network

Activity Timeline